Tag: IN.PACT Admiral
Medtronic issues voluntary recall for subset of IN.PACT Admiral and IN.PACT...
Medtronic recently voluntarily recalled a subset of its IN.PACT Admiral and IN.PACT AV paclitaxel-coated percutaneous transluminal angioplasty (PTA) balloon catheters due to the potential...
IN.PACT Admiral DCB performs well across wide range of clinical and...
In a pooled analysis of the predictors of drug-coated balloon (DCB) effectiveness, the IN.PACT Admiral DCB (Medtronic) performed well across a broad range of...
Episode 4: Real world data show IN.PACT Admiral DCB is “very...
In this penultimate episode of a special five-part series on the history of drug-coated balloons (DCBs), Jos van den Berg (Lugano, Switzerland) is joined...
VIVA 2021: IN.PACT Admiral DCB found to provide “high five-year freedom...
Real-world data drawn from the IN.PACT Global study looking at five-year freedom from clinically-driven target lesion revascularisation (TLR) among prespecified chronic total occlusion (CTO),...
Medtronic receives CE mark for 200mm and 250mm IN.PACT Admiral DCBs
Medtronic has announced CE mark approval and the European launch of the 200mm and 250mm IN.PACT Admiral drug-coated balloons (DCBs). The product is intended...
Lower-dose SurVeil DCB achieves non-inferiority with IN.PACT Admiral balloon
Kenneth Rosenfield (Boston, USA) speaks to Vascular News about the TRANSCEND trial, a non-inferiority randomised controlled trial, which looked to demonstrate safety and efficacy of the...
LINC 2021: Long-term data show sustained efficacy and safety of paclitaxel...
A key theme among the late-breaking trial data presented at LINC 2021 (The Leipzig Interventional Course; 25–29 January, online) was the emergence of long-term...
LINC 2021: Head-to-head trials take centre stage in drug-eluting technology late-breaking...
Data from two head-to-head trials on drug-eluting technologies in femoral artery treatment were presented during a late-breaking session at LINC 2021 (The Leipzig Interventional...
TOBA III clinical trial results published in the Journal of Vascular...
Intact Vascular has announced the peer-reviewed publication of its Tack optimised balloon angioplasty (TOBA) III 12-month clinical trial results in the Journal of Vascular Surgery.
The multi-centre, single-arm,...
BIOPACT-RCT set to compare Passeo-18 Lux and IN.PACT Admiral DCBs in...
iD3 Medical has announced that it has received approval in Belgium to initiate a randomised controlled trial, BIOPACT-RCT: a physician-initiated multicentre trial evaluating the...
Latest data from Philips reinforces the safety profile of Stellarex low-dose...
A new pooled analysis of patient-level data from Philips demonstrates the “strong safety profile” of the company's Stellarex drug-coated balloon (DCB) in above-the-knee studies,...
IN.PACT SFA five-year outcomes show sustained benefits of drug-coated balloon in...
The IN.PACT SFA trial’s co-principal investigator John Laird, from the Adventist Heart and Vascular Institute in St. Helena, USA, has presented the five-year outcomes...
IN.PACT SFA Trial five-year data and Total IN.PACT All-Subjects analysis presented...
The five-year and final results from the pivotal IN.PACT SFA Trial and one-year all-subjects results from the Total IN.PACT Pooled Analysis of the IN.PACT...
IN.PACT Admiral DCB launched in Japan
Medtronic plc has announced the full commercial launch of the IN.PACT Admiral drug-coated balloon (DCB) in Japan. The launch follows the completion of a...
IN.PACT Admiral DCB receives FDA approval for long SFA lesions
Medtronic has announced that it has received US Food and Drug Administration (FDA) approval for the IN.PACT Admiral drug-coated balloon (DCB) to treat long superficial...
Andrew Holden: Update on the IN.PACT AV Access trial
Andrew Holden spoke to Vascular News at LINC 2018 (Leipzig Interventional Course; 30 January–2 February, Leipzig, Germany) about the new data from the IN.PACT...
Two- and four-year IN.PACT Admiral drug-coated balloon data indicate good mid-...
Medtronic has released data reinforcing the durability and safety of the IN.PACT Admiral drug-coated balloon (DCB) in patients with peripheral artery disease (PAD). The...
IN.PACT Admiral drug-coated balloon is approved in Japan
Medtronic announced on 8 September 2017 that the IN.PACT Admiral drug-coated balloon (DCB) received approval from the Japanese Ministry of Health, Labour and Welfare...
Surmodics receives IDE approval to initiate SurVeil drug-coated balloon pivotal trial
Surmodics has received an investigational device exemption (IDE) from the US Food and Drug Administration (FDA) to initiate a pivotal clinical trial of the...
IN.PACT Admiral approved for reimbursement in France and Belgium
Medtronic has announced recent reimbursement approvals in both France and Belgium.
A Ministerial decree was published in the Official Journal of French Republic to enlist...
Leaving nothing behind: Is it time to move away from primary...
This educational supplement is only available in countries in Europe.
This educational supplement explores the concept of “leaving nothing behind" in the treatment of the superficial...
Global cohorts report drug-coated balloon success above the knee and “promising”...
Three global registries reported fresh data at the 2017 Leipzig Interventional Course (LINC; 24–27 January, Leipzig, Germany), all of which showed encouraging outcomes for...
Promising 12- and 24-month East Asian experiences for drug-coated balloons
Results from two Asian studies presented at LINC 2017 (24–27 January, Leipzig, Germany), show encouraging outcomes for drug-coated balloon versus percutaneous transluminal angioplasty treatment...
Medtronic announces Health Canada licence for IN.PACT Admiral drug-coated balloon
Medtronic Canada, a subsidiary of Medtronic, has announced it has obtained Health Canada licence for the IN.PACT Admiral drug-coated balloon. IN.PACT Admiral is a primary...
Japanese IN.PACT SFA study demonstrates clinical outcomes consistent with other trials
The one-year clinical outcomes from the MDT-2113 IN.PACT SFA Japan trial have been released. The data was recently presented by Osamu Iida, Kansai Rosai...
US FDA grants Medtronic investigational device exemption for IN.PACT Admiral AV...
Medtronic has received an investigational device exemption (IDE) from the US Food and Drug Administration (FDA) to initiate a study of the IN.PACT Admiral...
New data demonstate durability, safety and efficacy for Medtronic’s In.Pact Admiral...
New data, presented in a series of late-breaking clinical trial presentations at the Vascular Interventional Advances (VIVA) 2016 conference in Las Vegas, USA, have...
US FDA approves first drug-coated balloon for treatment of in-stent restenosis
The US Food and Drug Administration (FDA) has approved Medtronic’s IN.PACT Admiral drug-coated balloon as a treatment for in-stent restenosis in patients with peripheral...
Medtronic receives FDA approval for IN.PACT Admiral DCB 150mm lengths
Medtronic has received US Food and Drug Administration (FDA) approval for the IN.PACT Admiral drug-coated balloon (DCB) in longer, 150mm lengths. The 150mm length...
